Home About us Services Contact
 

News

In response, FLWS is sharpening its demand‑generation model, aiming to improve marketing contribution margin and efficiency. The firm is also expanding third‑party marketplace partnerships (Uber, DoorDash, Amazon, and Walmart.com), thereby driving customer reach and offsetting decline in its traditional channels. A loyalty‑program upgrade is slat...
Full article
30/01/2026 | 1-800-FLOWERS.COM, Inc.
Management highlighted a $15 million annualized run‑rate cost‑saving initiative for fiscal 2026, achieved through simplifying the organization and boosting operational efficiency. These savings come as a compensatory lever to offset revenue shortfalls, particularly in direct traffic and search‑engine visibility, which have weakened the company’s t...
Full article
30/01/2026 | 1-800-FLOWERS.COM, Inc.
1‑800‑Flowers.com (NASDAQ: FLWS) reported Q2 2026 earnings of $1.20 per share, beating the consensus estimate of $0.92 by 39.54 %. Revenue for the period was $702.18 million, a 0.23 % lift over expectations but still 9.2 % below the $775.49 million reported a year earlier. The company’s gross margin fell because of lower fixed‑cost absorption, hig...
Full article
30/01/2026 | 1-800-FLOWERS.COM, Inc.
The appointment coincides with the firm’s ongoing development of its telomere‑analysis platform, which underpins Telo Genomics’ diagnostic and prognostic tests. The company maintains a portfolio of over 160 peer‑reviewed publications and more than 30 clinical studies involving in excess of 3,000 patients. Its flagship product, Telo‑MM, is advanci...
Full article
30/01/2026 | Telomir Pharmaceuticals, Inc.
Telo Genomics Corp. (TSXV: TELO) announced that John Price will assume the role of Chief Financial Officer effective January 30 , 2026. Price comes with more than 30 years of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets, and holds a B.S. in Accounting from Pennsylvania State University. He...
Full article
30/01/2026 | Telomir Pharmaceuticals, Inc.
AOSL has a track record of exceeding consensus EPS estimates, having outperformed in the last four quarters. With a Zacks Rank of #2 (Buy) and the high ESP, analysts remain bullish on the company’s earnings prospects. The forthcoming February 5 results are expected to confirm a consensus‑EPS beat.
Full article
30/01/2026 | Alpha and Omega Semiconductor Limited
The Zacks Consensus Estimate has remained unchanged over the last 30 days, indicating that analysts have reassessed initial figures without significant adjustment. However, the Most Accurate Estimate exceeds this consensus, giving AOSL an Earnings Surprise Probability (ESP) of +62.50 %. This positive deviation increases the likelihood that the comp...
Full article
30/01/2026 | Alpha and Omega Semiconductor Limited
Alpha and Omega Semiconductor (AOSL) is projected to report a year‑over‑year earnings decline when the company releases its December 2025 quarterly results on February 5. Analysts forecast a loss of $0.08 per share, compared with a $0.43 profit in the same period last year, and anticipate revenues of $160 million—a 7.6 % drop from the previous year...
Full article
30/01/2026 | Alpha and Omega Semiconductor Limited
The company highlighted a robust backlog that should underpin growth in the coming year, and it forecasts historically high turnover for full‑year 2026, with a stronger second‑half contributed by higher shipments and improved execution. CEO Klas Forsström noted that profitability deficits are largely temporary and that the firm has implemented acti...
Full article
30/01/2026 | Munters Group AB (publ)
Munters Group AB reported a 191 % rise in Q4 order intake, largely driven by a 416 % increase in its Data Center Technologies (DCT) segment while AirTech order intake remained flat. Net sales fell 8 % on currency effects; adjusted EBITA margin slipped due to temporary tariff headwinds in DCT and lower volumes in AirTech. Leverage stood at 2.9×, ref...
Full article
30/01/2026 | Munters Group AB (publ)